SAN

77.86

-2.03%↓

SHL.DE

40.78

+1.39%↑

ACB

3.55

+5.65%↑

SAN

77.86

-2.03%↓

SHL.DE

40.78

+1.39%↑

ACB

3.55

+5.65%↑

SAN

77.86

-2.03%↓

SHL.DE

40.78

+1.39%↑

ACB

3.55

+5.65%↑

SAN

77.86

-2.03%↓

SHL.DE

40.78

+1.39%↑

ACB

3.55

+5.65%↑

SAN

77.86

-2.03%↓

SHL.DE

40.78

+1.39%↑

ACB

3.55

+5.65%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

20.8 0.73

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.35

Max

20.95

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+10.31% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	1. apr 2026

Turustatistika
By TradingEconomics
Turukapital	937M
Eelmine avamishind	20.07
Eelmine sulgemishind	20.8

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. veebr 2026, 23:57 UTC

Kuumad aktsiad

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12. veebr 2026, 23:35 UTC

Tulu

Suurimad hinnamuutused turgudel

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12. veebr 2026, 23:28 UTC

Tulu

Applied Materials Profit Rises on Soaring AI Demand -- Update

12. veebr 2026, 21:47 UTC

Tulu

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13. veebr 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12. veebr 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12. veebr 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12. veebr 2026, 23:33 UTC

Tulu

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12. veebr 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12. veebr 2026, 22:55 UTC

Tulu

Kuumad aktsiad

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12. veebr 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12. veebr 2026, 22:23 UTC

Tulu

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12. veebr 2026, 22:00 UTC

Tulu

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12. veebr 2026, 22:00 UTC

Tulu

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12. veebr 2026, 21:57 UTC

Tulu

XP 4Q Rev BRL4.95B >XP

12. veebr 2026, 21:52 UTC

Tulu

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12. veebr 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. veebr 2026, 21:47 UTC

Tulu

Morningstar 4Q Rev $641M >MORN

12. veebr 2026, 21:39 UTC

Tulu

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. veebr 2026, 21:38 UTC

Tulu

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

10.31% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR 10.31%

Kõrge 23 EUR

Madal 23 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.